

# AGENDA OVERVIEW

European Antibody Congress

World Immunotherapy Congress

World Biosimilar Congress

Clinical Trial Workshop Day 1 & 2

Day 1 - Monday 29th October 2018

Morning plenary keynote

Morning plenary keynote

Morning plenary keynote

Morning networking break

Plenary roundtables

Plenary roundtables

Plenary roundtables

Lunch

**Protein engineering and R&D**

- Engineering antibody formats
- Display of biologics

**Bispecifics development**

- Investor panel
- Regulatory updates
- Antibody naming

**Armed antibodies discovery**

- ADC and loaded antibodies
- Payload discovery
- Linker technology

**Investment and regulation**

- Investor panel
- Regulatory updates
- Antibody naming

**Immune checkpoint inhibitors**

- Approved Market Formats
- New Agents
- Combination Agents

**Cell therapy**

- Antigen Targets
- Cell Therapy for solid tumours
- Allogeneic gene therapy

Clinical trials workshops

**Market access strategies, opportunities and commercial challenges**

- Ensuring clinical adoption
- Bringing biosimilars to market
- Technology transfer
- Emerging markets

**Biosimilar Development**

- Manufacture and clinical case studies
- Clinical trials
- Demonstrating biosimilarity
- Opportunities in development

- Targeted workshops focusing on how we can reduce trial failure and improve patient experience
- Transforming clinical trials to meet demands of the future
- Case studies on disruptive technology within clinical trials

Closing keynote

Closing keynote

Closing keynote

HPAPI World Congress

Day 2 – Tuesday 30th October 2018

Opening keynotes: C-level panel

Opening keynotes: C-level panel

Opening keynotes: C-level panel

Opening keynotes

Morning refreshments

**Protein engineering and R&D**

- Antibody screening and analytics

**Bispecifics development / discovery**

- Advancing bispecifics
- Engineering bispecifics

**Armed antibodies discovery / development**

- Novel payloads
- ADC engineering

**AI in antibody discovery**

- Artificial intelligence and machine learning for antibody discovery

**Platform technology showcase**

- New technology for antibody discovery and development

**Immune checkpoint inhibitors**

- Approved Market Formats
- New Agents
- Combination Agents

**Cell therapy**

- Antigen Targets
- Cell Therapy for solid tumours
- Allogeneic gene therapy

**Market access strategies, opportunities and commercial challenges**

- Regulatory Updates
- Streamlining approval
- Case studies from benchtop to market

**Biosimilar Development**

- Demonstrating interchangeability
- Analytics, development & pharmacovigilance
- Harmonizing immunogenicity testing
- Characterization, assay development & extrapolation

**Speed Networking**

- Roundtables/workshops**
- Considerations for risk assessments
  - EHS challenges of new ADCs
  - Toxicological issues
  - Outsourcing
  - Adapting to guidelines
  - Containment systems: old vs new

Lunch

**CMC and developability**

- Antibody commercialisation and manufacture
- Protein production

**Bispecifics discovery**

- Bispecific combinations
- New technology and armed bispecifics

**Armed antibodies development**

- ADCs and armed antibodies in preclinical and clinical development

**AI in antibody discovery**

- AI and image analytics to develop new uses for pre-existing antibodies

**Platform technology showcase**

- Antibody characterisation
- Antibody manufacture

**Market access**

- Investor input
- Regulatory issues
- Commercialisation and manufacture

**Clinical trials**

- Workshops
- Challenges with clinical trials
- Case studies

**Market access strategies, opportunities and commercial challenges**

- IP and legal considerations

**Biosimilar Development**

- Development & Manufacturing strategies

**Containment, equipment, facility design**

- Containment technologies
- Adapting solutions for HPAPIS

**Occupational EH&S Toxicological limits**

- Control banding
- Using data

Closing keynotes

Closing keynotes

Closing keynotes

Closing keynotes

Day 3 – Wednesday 31st October 2018

**Novel targets and biomarker discovery**

- Early stage biomarker discovery
- Target development
- New biomarker development

**New technological advancements**

- Optimising expression and purification technologies
- New screening and analytical technologies

**mAbs**

- Updates on mAb discovery and development
- Antibody engineering and optimising expression

**Biomarkers**

- Technology
- Development
- New biomarkers in development

**Immunotherapy for solid tumours**

- Challenges for solid tumours
- Examples and pre/clinical development

**Combination therapy**

- Current development
- Case studies
- Lessons learned
- Challenges

**Oncolytic viral therapy and cancer vaccines**

- Early stage discovery
- Technological breakthroughs

**Outsourcing and manufacturing**

- Evolving vendor relationships
- Supply chain integration
- Case studies
- Manufacturing processes

**Drug safety and pharmacovigilance**

- Current development
- Challenges

**Guidelines and regulations**

- Aseptic facility design
- Cleaning requirements
- Update: EMA guidelines
- **Antibody drug conjugates**
- Site specific conjugation
- Case studies

Lunch

Closing plenary

Closing plenary

Closing plenary



For more information, contact Derek Cavanagh on +44 207 092 1297 or derek.cavanagh@terrapi.com



For more information, contact Alistair Wilmot on +44 207 092 1174 or alistair.wilmot@terrapi.com